Monday, January 23, 2012
Idera Pharmaceuticals Inc., of Cambridge, Mass., said a Phase Ib trial of Toll-like receptor 9 agonist IMO-2055 plus Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG) and Avastin (bevacizumab, Roche AG) in refractory non-small-cell lung cancer patients showed the combination was well tolerated and resulted in a disease control rate of 79 percent, median progression-free survival (PFS) of 5.6 months and median overall survival (OS) of 16 months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.